Jul 2 |
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
|
Jul 2 |
Veru (NASDAQ:VERU) investors are sitting on a loss of 89% if they invested three years ago
|
Jun 24 |
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
|
Jun 18 |
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
|
Jun 17 |
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
|
Jun 10 |
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
|
May 29 |
Comstock And 2 Other Stocks Under $2 Insiders Are Buying
|
May 22 |
Individual investors account for 48% of Veru Inc.'s (NASDAQ:VERU) ownership, while institutions account for 25%
|
May 22 |
Veru to Present at the Jefferies Global Healthcare Conference
|
May 15 |
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
|